Danaher Corporation $DHR Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lessened its position in Danaher Corporation (NYSE:DHR) by 1.2% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 795,431 shares of the conglomerate’s stock after selling 9,319 shares during the period. Thrivent Financial for Lutherans owned approximately 0.11% of Danaher worth $157,702,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. WFA of San Diego LLC purchased a new stake in shares of Danaher in the second quarter valued at about $26,000. Howard Hughes Medical Institute purchased a new position in Danaher during the second quarter worth $27,000. TruNorth Capital Management LLC purchased a new position in Danaher during the third quarter worth $28,000. Red Tortoise LLC raised its holdings in shares of Danaher by 175.0% in the second quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock worth $30,000 after acquiring an additional 98 shares during the last quarter. Finally, Tripletail Wealth Management LLC purchased a new stake in shares of Danaher in the third quarter valued at $31,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling

In other news, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the completion of the transaction, the senior vice president directly owned 14,553 shares in the company, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Teri List sold 3,298 shares of the company’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the completion of the sale, the director directly owned 20,762 shares of the company’s stock, valued at $4,702,593. The trade was a 13.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 30,248 shares of company stock valued at $6,609,663 in the last quarter. Company insiders own 11.10% of the company’s stock.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q4 results beat on EPS and management set FY2026 EPS guidance of $8.35–$8.50, which is above many street estimates and supports upside to earnings expectations. Danaher (DHR) Tops Q4 Earnings Estimates, Issues Solid 2026 Outlook
• Positive Sentiment: JPMorgan raised its price target to $275 and kept an overweight rating, signaling continued bullish sentiment among some large sell‑side shops. Benzinga
• Positive Sentiment: Molecular Devices (a Danaher business) announced a partnership to expand automated, AI‑ready research solutions — a product/market development that supports longer‑term growth in lab automation and software‑enabled sales. Molecular Devices Expands Access to Automated, AI-Ready Research Solutions
• Neutral Sentiment: Goldman Sachs trimmed its target slightly to $265 but maintained a buy rating, a modest calibration that still implies material upside but signals some caution. MarketScreener
• Neutral Sentiment: Earnings call transcripts and highlights show management emphasizing free cash flow and balance sheet strength, but a cautious tone on near‑term demand. These details provide context but are not unambiguously positive or negative. Danaher (DHR) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Market commentary and headlines framed the report as “in‑line” on sales and cautioned investors that the post‑earnings dip may not be a good buying opportunity, which likely amplified selling pressure. Danaher Stock Plunge Does Not Represent A Good Entry Point
• Negative Sentiment: Despite the EPS beat, some outlets highlighted the stock drop after an essentially in‑line revenue/outlook, reinforcing bearish sentiment in the short term. Danaher drops after in-line earnings outlook
• Negative Sentiment: Valuation is elevated (P/E ~43) versus historical averages, which can make the stock more sensitive to any guidance softness or mixed indicators.

Wall Street Analyst Weigh In

DHR has been the topic of several recent analyst reports. JPMorgan Chase & Co. upped their price objective on shares of Danaher from $270.00 to $275.00 and gave the company an “overweight” rating in a research note on Thursday. Barclays raised their price target on Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Morgan Stanley initiated coverage on shares of Danaher in a research note on Monday, December 1st. They set an “overweight” rating and a $270.00 price objective for the company. KeyCorp reissued an “overweight” rating on shares of Danaher in a research report on Thursday. Finally, Wells Fargo & Company upped their price target on shares of Danaher from $230.00 to $240.00 and gave the stock an “equal weight” rating in a research report on Monday, December 15th. Twenty investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $252.32.

Danaher Price Performance

Shares of NYSE DHR opened at $218.82 on Friday. The business has a 50 day moving average price of $230.60 and a two-hundred day moving average price of $214.11. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $242.80. The firm has a market cap of $154.56 billion, a PE ratio of 43.42, a price-to-earnings-growth ratio of 3.12 and a beta of 0.89. The company has a quick ratio of 1.10, a current ratio of 1.87 and a debt-to-equity ratio of 0.35.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, January 28th. The conglomerate reported $2.23 earnings per share for the quarter, topping the consensus estimate of $2.14 by $0.09. The company had revenue of $6.84 billion during the quarter, compared to analyst estimates of $6.79 billion. Danaher had a net margin of 14.71% and a return on equity of 10.81%. The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period last year, the business earned $2.14 EPS. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. Sell-side analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 30th. Stockholders of record on Friday, December 26th were given a dividend of $0.32 per share. The ex-dividend date was Friday, December 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s dividend payout ratio is currently 25.40%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.